Quick answer
Matteo Ricci is a Health Policy and Access Writer for Europe & United Kingdom pharmaceutical intelligence editor on NovaPharmaNews, with 24 published articles covering EMA regulatory actions, clinical development, and market-moving news. Matteo Ricci reports on HTA evaluations, pricing negotiations, and reimbursement updates across major EU markets. His 10 years in health economics coverage focus on the practical impact of payer evidence standards for launch sequencing.
About Matteo Ricci
Matteo Ricci reports on HTA evaluations, pricing negotiations, and reimbursement updates across major EU markets. His 10 years in health economics coverage focus on the practical impact of payer evidence standards for launch sequencing.
Coverage focus
Topics and beats Matteo covers across Europe & United Kingdom.
Explore related intelligence
Entity directories linked from this author's coverage.
- Global markets Cross-region command center
- Company directory Sponsor & marketer profiles
- Drug profiles INN & regulatory status
- Clinical trials hub Stage & therapy filters
- Pipeline programs R&D intelligence
- Patent landscape US & EP IP moats
- Event calendar Congress catalysts
- Regulatory reference Submission types & pathways
Articles by Matteo Ricci
CRISPR Therapeutics Reports Q1 2026 Results as CASGEVY Gene Therapy Gains Global Regulatory Approval
CRISPR Therapeutics reports Q1 2026 financial results highlighting CASGEVY's approval in 10+ countries for sickle cell disease and beta thalassemia treatment.
FDA Approves Auvelity for MDD: A New Antidepressant Option
The FDA has granted approval for Auvelity, a new oral medication for major depressive disorder (MDD) in adults. This approval introduces a novel treatment option with a distinct mechanism of action and a reported rapid onset of therapeutic effect.
uniQure AMT-130 Gene Therapy Advances Toward UK Approval for Huntington's Disease Treatment
uniQure completes successful UK MHRA pre-submission meeting for AMT-130 Huntington's disease gene therapy, targeting Q3 2026 marketing authorization application.
Cerus Corporation INTERCEPT Blood System Advances Through European Regulatory Review and Phase 3 Trials
Cerus Corporation's INTERCEPT Blood System progresses through European regulatory review while Phase 3 RedeS trial readout and new INT200 device submission planned.
NMPA Approval Lung Cancer Immunotherapy: PD-1/PD-L1 Combo Trends 2025
This article delves into the NMPA's approval landscape for lung cancer immunotherapy, highlighting the emerging trends of PD-1/PD-L1 combination therapies by 2025.
African Medicines Agency Implementation: Transforming Regulatory Harmonization & Market Access
The African Medicines Agency is set to revolutionize regulatory processes, ensuring faster market access for vital medicines across the continent.
EMA Conditional Approval Pathway: Insights from Repotrectinib Oncology Approval
This article delves into the EMA Conditional Approval Pathway, highlighting key insights from the oncology approval of Repotrectinib for advanced cancer treatment.
SAHPRA accelerated approval oncology: What You Need to Know
Learn about SAHPRA's accelerated approval process for oncology, which expedites access to essential cancer treatments, including Pembrolizumab.
LATAM Oncology Clinical Trials: Expansion Trends & Success Factors 2024
Discover the latest trends in LATAM oncology clinical trials for 2024, highlighting drug innovations and critical factors driving success in cancer research.
EMA Conditional Marketing Authorizations: 5-Year Review of Oncology Drug Approvals
This article reviews the EMA's conditional marketing authorizations over the past five years, focusing on oncology drugs and their impact on cancer treatment accessibility.
VivoSim Labs Launches AI Tool to Predict Drug-Induced Diarrhea Without Animal Testing
VivoSim Labs unveils AI prediction platform using human intestinal models to forecast gastrointestinal toxicity, eliminating need for animal testing.
Advanced Bifurcation Systems Acquires Svelte Medical Systems in Major Coronary Stent Deal
Advanced Bifurcation Systems Inc. acquires Svelte Medical Systems, expanding its coronary angioplasty portfolio with drug-eluting stents and regulatory approvals.
Zentiva Appeals EU Court Decision on Urban Wastewater Directive Affecting Generic Medicine Access
Zentiva and generic drugmakers challenge EU Urban Wastewater Directive at CJEU, citing concerns over patient access and medicine affordability in Europe.
Crinetics Pharmaceuticals Receives EU Approval for PALSONIFY (Paltusotine), First Oral Daily Acromegaly Treatment
Crinetics Pharmaceuticals announces European Commission approval of PALSONIFY (paltusotine), the first once-daily oral therapy for acromegaly in adults.
Pharma Supercomputer: Eli Lilly and NVIDIA’s AI-Powered Breakthrough
Eli Lilly and NVIDIA have partnered to build the pharmaceutical industry's most powerful supercomputer. This AI-driven innovation aims to accelerate drug discovery and development, enhancing computational research capabilities globally.
African Medicines Agency: Harmonizing Regulatory Standards to Boost Pharma Access
The African Medicines Agency aims to streamline regulatory processes, improving access to vital medications such as antiretrovirals and boosting public health across Africa.
EMA Issues Positive Opinion for Itvisma (Onasemnogene Abeparvovec) Gene Therapy for Spinal Muscular Atrophy
European Medicines Agency issues positive opinion for Itvisma, a one-time gene therapy for spinal muscular atrophy in infants and children.
EMA Issues Positive Opinion for Cenrifki (Tolebrutinib) Multiple Sclerosis Treatment
European Medicines Agency issues positive opinion for Cenrifki (tolebrutinib), a potential new oral treatment for multiple sclerosis patients.
SFDA accelerated approval oncology: ANKTIVA's breakthrough in NSCLC treatment
ANKTIVA has received SFDA accelerated approval, marking a significant breakthrough in the treatment of non-small cell lung cancer (NSCLC).
COFEPRIS Approval Trends: What You Need to Know About Mexico’s Innovative Medicines Access
Stay informed about COFEPRIS approval trends and how they impact access to innovative medicines in Mexico, ensuring timely availability for patients.
FDA Guidance on Accelerated Approval: Key Updates for Oncology Drugs
This article explores the latest FDA guidance on accelerated approval for oncology drugs, highlighting critical updates that impact drug development and patient access.
Next-Generation Immunotherapy: Beyond PD-1/PD-L1 Inhibition in US Oncology
This article delves into next-generation immunotherapy strategies that extend beyond PD-1/PD-L1 inhibition, highlighting advancements in cancer treatment.
Cost-Effectiveness of Nivolumab plus Ipilimumab in LATAM's Renal Cell Carcinoma Market
This article analyzes the economic viability of Nivolumab plus Ipilimumab for Renal Cell Carcinoma, highlighting its impact on LATAM's healthcare landscape.
SAB Biotherapeutics SAB-142 Shows C-Peptide Preservation in Type 1 Diabetes Phase 1 Trial
SAB-142 preserved C-peptide in all 4 Type 1 diabetes patients, with 3 showing super responder profiles and improved glycemic control in Phase 1 trial.
Frequently asked questions
Who writes NovaPharmaNews articles?
Each story is attributed to a named editor or analyst with a public author profile. Profiles list credentials, coverage focus, and every published article so readers and AI systems can verify expertise and trace claims to a accountable journalist.
How do I find more coverage from this author?
Scroll to the article archive on this page, or use the topic chips linked from the author’s specializations. The regional authors directory lists every active contributor in this edition.
How does author coverage connect to companies and pipeline data?
Articles link to company profiles, drug INN pages, clinical trials, and pipeline programs when entities are tagged. Use the intelligence spokes on each story or browse topic hubs from the author’s beat.